SL
SLP.US Simulations Plus Inc
- Market cap
- USD 374M
- P/E
- 46.3x
- P/B
- 2.69x
- ROE
- 8.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is SLP.US undervalued?
Graham numberSLP.US trades 135.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Simulations Plus Inc fundamental analysis
No fundamental analysis for Simulations Plus Inc yet.
Simulations Plus Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides…
Full company profileSimulations Plus Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Simulations Plus Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 18.3M | 24.1M | 29.7M | 34.0M | 41.6M | 46.5M | 53.9M | 59.6M | 70.0M | 79.2M | 86.1M |
| Gross Profit | 14.0M | 17.8M | 21.7M | 24.9M | 30.9M | 35.9M | 43.1M | 47.9M | 43.2M | 46.2M | 56.2M |
| Operating Income | 5.86M | 8.26M | 10.3M | 10.6M | 11.6M | 11.3M | 14.9M | 8.73M | 6.13M | -70.7M | 14.5M |
| EBITDA | - | 10.4M | 13.0M | 13.3M | 14.3M | 14.7M | 18.7M | 12.6M | 18.1M | 14.7M | 20.3M |
| Net Income | 3.84M | 5.79M | 8.93M | 8.58M | 9.33M | 9.78M | 12.5M | 9.96M | 9.95M | -64.7M | 11.7M |
| EPS | 0.22 | 0.33 | 0.50 | 0.48 | 0.50 | 0.47 | 0.60 | 0.49 | 0.49 | -3.22 | 0.58 |
| Balance Sheet | |||||||||||
| Total Assets | 27.8M | 38.5M | 44.1M | 46.1M | 170M | 182M | 191M | 193M | 208M | 132M | 153M |
| Total Liabilities | 5.08M | 12.7M | 12.2M | 8.41M | 13.8M | 15.8M | 12.3M | 22.6M | 25.2M | 7.14M | 13.9M |
| Shareholders' Equity | 22.7M | 25.8M | 31.9M | 37.7M | 156M | 166M | 178M | 170M | 182M | 125M | 139M |
| Cash & Short-term Investments | 8.03M | 6.22M | 9.40M | 11.4M | 116M | 124M | 128M | 115M | 20.3M | 32.4M | 50.0M |
| Total Debt | 482M | - | - | - | 927K | 1.28M | 1.40M | 1.20M | 1.01M | 616K | 487K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.13M | 6.88M | 9.29M | 11.6M | 10.9M | 19.2M | 17.9M | 21.9M | 13.3M | 18.1M | 27.9M |
| Capital Expenditure | 71.4K | 1.56M | 2.33M | 1.96M | 2.58M | 4.58M | 3.97M | 4.27M | 566K | 713K | 2.34M |
| Free Cash Flow | - | 5.32M | 6.96M | 9.68M | 8.33M | 14.6M | 13.9M | 17.6M | 12.8M | 17.4M | 25.5M |
| Ratios | |||||||||||
| ROE | 16.9% | 22.4% | 28.0% | 22.8% | 6.0% | 5.9% | 7.0% | 5.9% | 5.5% | -51.9% | 8.4% |
| ROA | 13.8% | 15.0% | 20.2% | 18.6% | 5.5% | 5.4% | 6.6% | 5.2% | 4.8% | -49.1% | 7.7% |
| Net Profit Margin | 21.0% | 24.0% | 30.1% | 25.3% | 22.4% | 21.1% | 23.2% | 16.7% | 14.2% | -81.7% | 13.6% |
| Debt to Equity | 21.19x | - | - | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Simulations Plus Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 29, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 4.80M | 0.24 | 48.2% |
| 2023 | USD 4.81M | 0.23 | 48.3% |
| 2022 | USD 4.85M | 0.23 | 38.8% |
| 2021 | USD 4.81M | 0.23 | 49.2% |
| 2020 | USD 4.25M | 0.23 | 45.5% |
| 2019 | USD 4.20M | 0.23 | 48.9% |
| 2018 | USD 4.16M | 0.23 | 46.6% |
| 2017 | USD 3.45M | 0.20 | 59.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Oct 2, 2007.
Who owns Simulations Plus Inc
- Insiders 16.91%
- Institutions 79.24%
- Public & others 3.85%
- Shares outstanding 20.2M
- Free float 16.8M
Top funds holding SLP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| First Eagle Small Cap Opportunity I | 787K | 3.89% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 537K | 2.66% | 0.00% | Sep 2026 |
| Tributary Small Company Instl | 263K | 1.30% | -14.31% | Sep 2026 |
| Herald Ord | 200K | 0.99% | 0.00% | Mar 2026 |
| Fidelity Small Cap Index | 187K | 0.93% | 0.00% | Aug 2026 |
| Carmignac Pf Merger Arb Plus I EUR Acc | 163K | 0.80% | 0.00% | Aug 2026 |
| North Star Micro Cap I | 145K | 0.72% | 0.00% | Sep 2026 |
| AB Merger Arbitrage S1 USD | 108K | 0.54% | +17.35% | Sep 2026 |
| GAMCO Intl SICAV Merger Arbtrg I (USD) | 107K | 0.53% | 0.00% | Jun 2026 |
| Vanguard Russell 2000 ETF | 99.9K | 0.49% | +1.42% | Sep 2026 |
| Fidelity Extended Market Index | 77.6K | 0.38% | -8.60% | Sep 2026 |
| First Eagle US Small Cap Opp I-UC | 72.5K | 0.36% | 0.00% | Sep 2026 |
| Stork Fund Dynamic MultiStrategies O EUR | 70.2K | 0.35% | 0.00% | Jun 2026 |
| Vanguard Health Care ETF | 52.7K | 0.26% | +0.11% | Sep 2026 |
| North Star Small Cap Value Investor | 50.0K | 0.25% | 0.00% | Sep 2026 |
| Buffalo Early Stage Growth Fd | 48.0K | 0.24% | -2.61% | Jun 2026 |
| Nicholas Limited Edition I | 46.9K | 0.23% | -76.24% | Mar 2026 |
| Schwab Small Cap Index | 41.8K | 0.21% | 0.00% | Sep 2026 |
| Fidelity Monthly Income Series F | 37.2K | 0.18% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 35.1K | 0.17% | +220.03% | Aug 2026 |
Top institutions holding SLP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| First Light Asset Management, LLC | 2.79M | 13.81% | +6.07% | Jun 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 2.14M | 10.59% | +188.54% | Jun 2026 |
| BlackRock Inc | 1.50M | 7.43% | +19.94% | Jun 2026 |
| Vanguard Capital Management, LLC | 741K | 3.67% | +0.24% | Jun 2026 |
| Kennedy Capital Management Inc | 539K | 2.67% | +38.47% | Jun 2026 |
| Tributary Capital Management, LLC | 538K | 2.66% | -1.85% | Jun 2026 |
| Geode Capital Management, LLC | 440K | 2.18% | +17.44% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 411K | 2.03% | -35.11% | Jun 2026 |
| State Street Corp | 383K | 1.89% | +6.13% | Jun 2026 |
| JPMorgan Chase & Co | 326K | 1.61% | +199.05% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 316K | 1.56% | -64.41% | Jun 2026 |
| The Goldman Sachs Group Inc | 313K | 1.55% | -17.68% | Jun 2026 |
| AQR Capital Management LLC | 300K | 1.49% | +88.13% | Jun 2026 |
| North Star Investment Management Corp | 219K | 1.08% | +11.08% | Jun 2026 |
| Jane Street Group LLC | 209K | 1.03% | +546.75% | Jun 2026 |
| Glazer Capital, LLC | 202K | 1.00% | 0.00% | Jun 2026 |
| Herald Investment Management Ltd | 200K | 0.99% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 183K | 0.91% | -9.73% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 170K | 0.84% | +12.47% | Jun 2026 |
| Rockefeller Capital Management L.P. | 169K | 0.83% | -71.29% | Jun 2026 |
Simulations Plus Inc company profile
- Company name
- Simulations Plus Inc
- Ticker
- SLP.US
- Exchange
- USA Stocks
- Listed since
- Jun 18, 1997
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 212
- Fiscal year end
- August
- Address
- 800 Park Offices Drive, Research Triangle Park, NC, United States, 27709
- Phone
- 661 723 7723
- Website
- simulations-plus.com
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina. As of October 6, 2026, Simulations Plus, Inc. was taken private.
Simulations Plus Inc management
6- Mr. Shawn M. O'ConnorChief Executive Officer · born 1960
- Mr. William FrederickCFO, Executive VP & Corporate Secretary · born 1964
- Mr. Joshua FoheyChief Operating Officer · born 1983
- Mr. John Anthony DiBella M.S.Chief Revenue Officer · born 1980
- Ms. Jill Fiedler-Kelly M.S.President of Services Solutions · born 1970
- Mr. Steven ChangGlobal Head of Strategic Alliances · born 1968